Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis

Peter H Gilligan, Damian G Downey, J Stuart Elborn, Patrick A Flume, Sebastian Funk, Deirdre Gilpin, Timothy J Kidd, John McCaughan, B Cherie Millar, Philip G Murphy, Jacqueline C Rendall, Michael M Tunney, John E Moore

Research output: Contribution to journalArticle

2 Citations (Scopus)
56 Downloads (Pure)

Abstract

Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.

Original languageEnglish
Pages (from-to)1-23
JournalJournal of Clinical Microbiology
Early online date06 Jun 2018
DOIs
Publication statusEarly online date - 06 Jun 2018
Externally publishedYes

Fingerprint

Cystic Fibrosis
Infection
Lung
Pneumonia
Anti-Bacterial Agents
Therapeutics

Cite this

Gilligan, Peter H ; Downey, Damian G ; Elborn, J Stuart ; Flume, Patrick A ; Funk, Sebastian ; Gilpin, Deirdre ; Kidd, Timothy J ; McCaughan, John ; Millar, B Cherie ; Murphy, Philip G ; Rendall, Jacqueline C ; Tunney, Michael M ; Moore, John E. / Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis. In: Journal of Clinical Microbiology. 2018 ; pp. 1-23.
@article{7eae429cd13547ee89f08ba9fa19642b,
title = "Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis",
abstract = "Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.",
author = "Gilligan, {Peter H} and Downey, {Damian G} and Elborn, {J Stuart} and Flume, {Patrick A} and Sebastian Funk and Deirdre Gilpin and Kidd, {Timothy J} and John McCaughan and Millar, {B Cherie} and Murphy, {Philip G} and Rendall, {Jacqueline C} and Tunney, {Michael M} and Moore, {John E}",
note = "Copyright {\circledC} 2018 American Society for Microbiology.",
year = "2018",
month = "6",
day = "6",
doi = "10.1128/JCM.00193-18",
language = "English",
pages = "1--23",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",

}

Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis. / Gilligan, Peter H; Downey, Damian G; Elborn, J Stuart; Flume, Patrick A; Funk, Sebastian; Gilpin, Deirdre; Kidd, Timothy J; McCaughan, John; Millar, B Cherie; Murphy, Philip G; Rendall, Jacqueline C; Tunney, Michael M; Moore, John E.

In: Journal of Clinical Microbiology, 06.06.2018, p. 1-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis

AU - Gilligan, Peter H

AU - Downey, Damian G

AU - Elborn, J Stuart

AU - Flume, Patrick A

AU - Funk, Sebastian

AU - Gilpin, Deirdre

AU - Kidd, Timothy J

AU - McCaughan, John

AU - Millar, B Cherie

AU - Murphy, Philip G

AU - Rendall, Jacqueline C

AU - Tunney, Michael M

AU - Moore, John E

N1 - Copyright © 2018 American Society for Microbiology.

PY - 2018/6/6

Y1 - 2018/6/6

N2 - Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.

AB - Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.

U2 - 10.1128/JCM.00193-18

DO - 10.1128/JCM.00193-18

M3 - Article

C2 - 29875191

SP - 1

EP - 23

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

ER -